JP2016506388A5 - - Google Patents

Download PDF

Info

Publication number
JP2016506388A5
JP2016506388A5 JP2015545868A JP2015545868A JP2016506388A5 JP 2016506388 A5 JP2016506388 A5 JP 2016506388A5 JP 2015545868 A JP2015545868 A JP 2015545868A JP 2015545868 A JP2015545868 A JP 2015545868A JP 2016506388 A5 JP2016506388 A5 JP 2016506388A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
nos
sequence consisting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015545868A
Other languages
English (en)
Japanese (ja)
Other versions
JP6499971B2 (ja
JP2016506388A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/073540 external-priority patent/WO2014089416A1/en
Publication of JP2016506388A publication Critical patent/JP2016506388A/ja
Publication of JP2016506388A5 publication Critical patent/JP2016506388A5/ja
Application granted granted Critical
Publication of JP6499971B2 publication Critical patent/JP6499971B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015545868A 2012-12-07 2013-12-06 抗ｃｄ３８抗体及びレナリドマイドを含む組成物 Active JP6499971B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261734524P 2012-12-07 2012-12-07
US61/734,524 2012-12-07
US201361769247P 2013-02-26 2013-02-26
US61/769,247 2013-02-26
US201361808372P 2013-04-04 2013-04-04
US61/808,372 2013-04-04
PCT/US2013/073540 WO2014089416A1 (en) 2012-12-07 2013-12-06 Compositions comprising anti-cd38 antibodies and lenalidomide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019003132A Division JP2019070020A (ja) 2012-12-07 2019-01-11 抗ｃｄ３８抗体及びレナリドマイドを含む組成物

Publications (3)

Publication Number Publication Date
JP2016506388A JP2016506388A (ja) 2016-03-03
JP2016506388A5 true JP2016506388A5 (enExample) 2017-01-19
JP6499971B2 JP6499971B2 (ja) 2019-04-10

Family

ID=50884019

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015545868A Active JP6499971B2 (ja) 2012-12-07 2013-12-06 抗ｃｄ３８抗体及びレナリドマイドを含む組成物
JP2019003132A Pending JP2019070020A (ja) 2012-12-07 2019-01-11 抗ｃｄ３８抗体及びレナリドマイドを含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019003132A Pending JP2019070020A (ja) 2012-12-07 2019-01-11 抗ｃｄ３８抗体及びレナリドマイドを含む組成物

Country Status (31)

Country Link
EP (2) EP3597191A1 (enExample)
JP (2) JP6499971B2 (enExample)
KR (2) KR102193045B1 (enExample)
CN (1) CN105263520B (enExample)
AR (1) AR093844A1 (enExample)
AU (2) AU2013355064B2 (enExample)
BR (1) BR112015012987A2 (enExample)
CA (1) CA2893946A1 (enExample)
CL (2) CL2015001558A1 (enExample)
CY (2) CY1122478T1 (enExample)
DK (1) DK2928495T3 (enExample)
ES (1) ES2731548T3 (enExample)
HR (1) HRP20191034T1 (enExample)
HU (3) HUE044142T2 (enExample)
IL (2) IL239234B (enExample)
LT (2) LT2928495T (enExample)
LU (1) LUC00187I2 (enExample)
MX (2) MX366296B (enExample)
MY (1) MY191601A (enExample)
NL (1) NL301079I2 (enExample)
NZ (1) NZ709215A (enExample)
PH (1) PH12015501263A1 (enExample)
PL (1) PL2928495T3 (enExample)
PT (1) PT2928495T (enExample)
RS (1) RS58829B1 (enExample)
RU (1) RU2698911C2 (enExample)
SG (3) SG11201504315WA (enExample)
SI (1) SI2928495T1 (enExample)
TW (2) TW201919699A (enExample)
UA (1) UA118255C2 (enExample)
WO (1) WO2014089416A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
WO2015195555A1 (en) * 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
US10617757B2 (en) 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
JP6802791B2 (ja) 2014-12-04 2020-12-23 ヤンセン バイオテツク，インコーポレーテツド 急性骨髄性白血病の治療のための抗ｃｄ３８抗体
EP4553157A3 (en) 2015-05-20 2025-07-23 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
UA125115C2 (uk) 2015-06-22 2022-01-12 Янссен Байотек, Інк. Спосіб лікування суб'єкта, який має множинну мієлому (мм)
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
JP7027321B2 (ja) 2015-11-03 2022-03-01 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体の皮下製剤及びその使用
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
JP7316930B2 (ja) 2016-07-15 2023-07-28 武田薬品工業株式会社 形質芽細胞及び形質細胞枯渇療法に対する応答を評価するための方法及び材料
JP2021502961A (ja) 2017-10-31 2021-02-04 ヤンセン バイオテツク，インコーポレーテツド 高リスク多発性骨髄腫の治療方法
CN112739715A (zh) 2018-01-12 2021-04-30 武田药品工业株式会社 抗cd38抗体的皮下给药
KR102286500B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
KR102286499B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드를 포함하는 약제학적 조성물
WO2019199135A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
JP7581052B2 (ja) * 2018-04-13 2024-11-12 サムヤン ホールディングス コーポレイション レナリドミドの経口用コーティング錠剤組成物
JP2021518424A (ja) * 2018-04-13 2021-08-02 サムヤン バイオファーマシューティカルズ コーポレイションＳａｍｙａｎｇ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ 様々な用量のレナリドミドの経口用錠剤組成物
KR20220080044A (ko) 2018-05-16 2022-06-14 얀센 바이오테크 인코포레이티드 암 요법에 사용하기 위한 bcma/cd3 및 gprdc5d/cd3 이중특이성 항체
IL281845B2 (en) * 2018-10-01 2025-06-01 Celgene Corp Combination therapy comprising 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and daratumumab for the treatment multiple myeloma
KR20220002891A (ko) * 2019-03-15 2022-01-07 모르포시스 아게 자가항체-매개 자가면역 질병의 치료를 위한 항-cd38 항체 및 이의 약제학적 조성물
CN113993543B (zh) * 2019-06-10 2024-07-12 武田药品工业株式会社 使用抗cd38抗体的组合疗法
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
IL292181A (en) * 2019-10-31 2022-06-01 Morphosys Ag Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
KR20220159947A (ko) 2019-12-05 2022-12-05 사노피-아벤티스 유.에스. 엘엘씨 피하 투여를 위한 항-cd38 항체의 제형
US20250277051A1 (en) * 2021-08-02 2025-09-04 Hangzhou Unogen Biotech, Ltd Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
WO1998046645A2 (en) 1997-04-14 1998-10-22 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO2006068185A1 (ja) * 2004-12-21 2006-06-29 Nippon Kayaku Kabushki Kaisha エポキシ樹脂、エポキシ樹脂組成物及びその硬化物
MX2007011064A (es) * 2005-03-23 2008-02-19 Genmab As Anticuerpos contra cd38 para tratamiento de mieloma multiple.
TR201910145T4 (tr) * 2006-09-26 2019-08-21 Genmab As Tümörlerin tedavi edilmesine yönelik anti-CD38 artı kortikosteroidler artı bir kortikosteroid-olmayan kemoterapötik.
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2191840A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191843A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
PT2621531T (pt) * 2010-09-27 2017-03-13 Morphosys Ag Anticorpo anti-cd38 e lenalidomida ou bortezomibe para o tratamento de mieloma múltiplo e linfoma não-hodgkins
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38

Similar Documents

Publication Publication Date Title
JP2016506388A5 (enExample)
JP2016514148A5 (enExample)
RU2015127089A (ru) Композиции, содержащие антитела к cd38 и леналидомид
JP2016536314A5 (enExample)
JP2014076062A5 (enExample)
JP2017048208A5 (enExample)
RU2015143462A (ru) Композиции, включающие антитела к cd38 и карфилзомиб
FI3932951T3 (fi) Menetelmiä ihosyövän hoitamiseksi antamalla PD-1-inhibiittoria
JP2018534933A5 (enExample)
JP2014533279A5 (enExample)
RU2018105846A (ru) Комбинация антагониста pd-1 с ингибитором egfr
HRP20201656T1 (hr) Neutralizacija inhibitornih putova u limfocitima
JP2010500370A5 (enExample)
JP2019531764A5 (enExample)
RU2015110981A (ru) Комбинации и их применение
JP2015532292A5 (enExample)
JP2020503891A5 (enExample)
JP2017507954A5 (enExample)
JP2010500371A5 (enExample)
JP2017515815A5 (enExample)
JP2012523417A5 (enExample)
JP2017525730A5 (enExample)
JP2017503820A5 (enExample)
JP2012136541A5 (enExample)
JP2017507953A5 (enExample)